Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles. [PDF]
J Virol, 2017 ABSTRACT There are currently no approved therapeutics or vaccines to treat or protect against the severe hemorrhagic fever and death caused by Ebola virus (EBOV). Ebola virus-like particles (EBOV VLPs) consisting of the matrix protein VP40, the glycoprotein (GP), and the nucleoprotein (NP) are highly immunogenic and protective in nonhuman ...
Schweneker M +13 more
europepmc +5 more sources
The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host [PDF]
, 2018 African horse sickness (AHS) is a lethal equine disease transmitted by Culicoides biting midges and caused by African horse sickness virus (AHSV). AHS is endemic to sub-Saharan Africa, but devastating outbreaks have been recorded periodically outside ...
Eva Calvo-Pinilla +4 more
openalex +4 more sources
Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara [PDF]
Microorganisms, 2013 The production of several viral vaccines depends on chicken embryo fibroblasts or embryonated chicken eggs. To replace this logistically demanding substrate, we created continuous anatine suspension cell lines (CR and CR.pIX), developed chemically ...
Volker Sandig +4 more
doaj +4 more sources
Stability of the HSV-2 US-6 Gene in the del II, del III, CP77, and I8R-G1L Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells [PDF]
Vaccines, 2020 The modified vaccinia virus Ankara (MVA), a severely attenuated strain of vaccinia virus, is a promising vector platform for viral-vectored vaccine development because of its attributes of efficient transgene expression and safety profile, among others ...
Vajini N. Atukorale +2 more
doaj +2 more sources
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates. [PDF]
Signal Transduct Target TherMayer L, Weskamm LM, Addo MM.
europepmc +3 more sources
Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells. [PDF]
PLoS Pathogens, 2020 Modified vaccinia virus Ankara (MVA) is an approved smallpox vaccine and a promising vaccine vector for other pathogens as well as for cancer therapeutics with more than 200 current or completed clinical trials.
Chen Peng +5 more
doaj +2 more sources
Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome-Coronavirus Spike Protein. [PDF]
J Infect Dis, 2023 Raadsen MP +14 more
europepmc +3 more sources
Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant. [PDF]
NPJ Vaccines, 2022 Yang N +6 more
europepmc +3 more sources
Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. [PDF]
PLoS ONE, 2010 BACKGROUND: Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus, has been used as vaccine delivery vector in preclinical and clinical studies against infectious diseases and malignancies.
Miriam Nörder +5 more
doaj +5 more sources
Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps? [PDF]
Viruses, 2017 Modified vaccinia virus Ankara (MVA) is the vector of choice for human and veterinary applications due to its strong safety profile and immunogenicity in vivo.
Malachy I. Okeke +7 more
doaj +2 more sources